10X Genomics (TXG) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
19 Apr, 2026The future of spatial biology
Spatial biology enables understanding of cell function by preserving tissue context at the molecular level.
Traditional tools compromise between throughput, resolution, and performance.
Introduction of Atera platform
Atera offers uncompromised spatial biology with whole transcriptome profiling.
Delivers up to 800 whole transcriptome samples of 1 cm² per year with single-cell sensitivity and subcellular resolution.
Redefines spatial biology from a specialized tool to a primary discovery engine.
Technical innovations and assay flexibility
Built on Chromium and Visium expertise, Atera's probe-based assay bypasses poly-A limitations for superior discovery.
Enables whole transcriptome coverage for fragmented or degraded samples, with gold-standard sensitivity and pinpoint specificity.
Offers modular assays: WTA for broad discovery, Select for targeted validation, and Custom for up to 3,000 gene targets.
Latest events from 10X Genomics
- 2026 proxy covers director elections, auditor ratification, and executive pay, with strong governance focus.TXG
Proxy filing24 Apr 2026 - Director elections, auditor ratification, and executive pay are up for vote at the annual meeting.TXG
Proxy filing24 Apr 2026 - Consumables growth and cost discipline drove revenue above guidance as losses narrowed.TXG
Q4 202513 Apr 2026 - Innovation and strong cash flow drive growth amid macro challenges and evolving customer needs.TXG
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Spatial consumables growth drove 4% revenue gain; 2024 guidance lowered amid macro headwinds.TXG
Q2 20242 Feb 2026 - Strong product launches and sales reorganization position the company for scalable growth.TXG
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 2024 revenue fell 1%, with strong consumables growth and new launches amid market headwinds.TXG
Q3 202418 Jan 2026 - Despite a tough 2024, new products and restructuring set the stage for robust future growth.TXG
Wolfe Research Healthcare Conference 202413 Jan 2026 - Strong 2025 results, innovation, and AI partnerships drive growth despite capital market headwinds.TXG
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026